Bilingualism's protective effects in Alzheimer's disease: Mechanisms of resilience and resistance

Wenfu Bao[1], Stephanie M. Grasso[1], Isabel Sala[2,3], M. Belén Sánchez-Saudinós[2,3], Judit Selma-González[2,3,4], Javier Arranz[2], Nuole Zhu[2,3], Sara Rubio-Guerra[2,3], Íñigo Rodríguez-Baz[2,3], María Carmona-Iragui[2,3,5], Isabel Barroeta[2,3,5], Ignacio Illán-Gala[2,3], Juan Fortea[2,3,5], Olivia Belbin[2,3], Lídia Vaqué-Alcázar[2,6], Marco Calabria[7], Eider M. Arenaza-Urquijo[8], Alexandre Bejanin[2,3], Daniel Alcolea[2,3], Alberto Lleó[2,3], Miguel Ángel Santos-Santos[2,3]

[1] Department of Speech, Language, and Hearing Sciences, The University of Texas at Austin, Austin, Texas, USA

[2] Sant Pau Memory Unit, IR SANT PAU, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

[3] Centro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain

[4] Institut de Neurociències, Universitat Autònoma de Barcelona, Barcelona, Spain

[5] Barcelona Down Medical Center, Fundació Catalana Síndrome de Down, Barcelona, Spain

[6] Department of Medicine, Faculty of Medicine and Health Sciences, Institute of Neurosciences, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain

[7] NeuroADaS Lab, Universitat Oberta de Catalunya, Barcelona, Spain

[8] Barcelona Institute for Global Health (ISGlobal), Barcelona, Spain

Corresponding author: Miguel Ángel Santos-Santos. Hospital de la Santa Creu i Sant Pau, Sant

Antoni Maria Claret, 167, 08025 Barcelona, Spain.

Email address: msantoss@santpau.cat

Abstract

INTRODUCTION: Bilingualism is among several lifestyle factors associated with protection against cognitive decline, yet the biological mechanisms through which it exerts these effects remain poorly understood.

METHODS: We compared neuropsychological functioning and biofluid markers of brain health between active ($n = 280$) and passive ($n = 287$) Spanish-Catalan bilinguals with biomarker-confirmed Alzheimer's disease (AD).

RESULTS: Active bilinguals outperformed passive bilinguals on tests assessing attention/executive functions, language, and visuospatial/visuomotor functioning, demonstrating resilience given the same AD biological stage across participants. Active bilinguals also exhibited significant differences in cerebrospinal fluid and plasma biomarkers of amyloid burden and neuroinflammation, suggesting both resilience and resistance to AD pathophysiologic mechanisms.

DISCUSSION: The protective effects of bilingual experience may engage both resilience and resistance to AD pathophysiology mechanisms. These results underscore the importance of capturing bilingualism in aging cohorts and the study of how lifestyle and sociocultural factors shape the biological expression of neurodegenerative disease.

1 Background

The protective effects of bilingualism have been observed across typical and pathological aging [1-6]. Despite mixed findings [7-9], many behavioral and neuroimaging studies report improved cognitive performance and preserved brain structure and network organization in bilinguals compared to monolinguals [4,6,10-12]. Accumulating evidence also links bilingualism to a delayed dementia onset of up to five years [5,13,14]. However, previous research has focused on participants without biomarker confirmation, and clinical diagnoses of Alzheimer's disease (AD) or mild cognitive impairment (MCI) based solely on symptoms and cognitive tests are often inaccurate [15]. Furthermore, compared to other cognitive reserve and/or resilience factors (e.g., education, physical activity, sex [16-22]), the biological mechanisms underlying bilingualism's putative protection have received less attention. Examining fluid biomarkers may reveal whether bilingualism influences cognitive decline by conferring resilience or resistance to AD-specific or non-specific neurodegenerative pathophysiologic mechanisms.

Literature exploring the biological basis of bilingualism's effects on cognitive decline, however, is nearly nonexistent except for two adjacent studies [23,24]. Notably, no research has examined individuals at the clinical dementia stage. Estanga et al [23] assessed cerebrospinal fluid (CSF) AD biomarkers in cognitively unimpaired participants and found lower CSF total tau (t-tau) in early bilinguals compared to monolinguals. This provides initial evidence that early bilingualism is associated with a more favorable CSF AD biomarker profile, suggesting resistance to tau pathology. In contrast, Grasso et al [24] observed a disadvantageous plasma biomarker profile in bilinguals with MCI who were impaired in verbal fluency, indicated by lower amyloid-beta (Aβ) 42/40 levels relative to bilinguals with MCI but unimpaired performance on verbal fluency.

Motivated by the prior work and the need for further investigation, the present study examines the effects of bilingualism on neuropsychological functioning and biofluid (i.e., CSF and plasma) markers of brain health. These include AD-specific pathophysiologic processes (Aβ and tau accumulation) as well as markers of non-specific neurodegeneration (e.g., neurofilament light or NfL) and neuroinflammation (e.g., glial fibrillary acidic protein or GFAP). Leveraging a cohort [25] with CSF biomarker-confirmed AD (i.e., Aβ and tau positive, A+T+ [26]) categorized into active vs. passive bilingual groups (further described in the section below), we explore the biological mechanisms, through the lens of resilience and resistance, that may subserve bilingualism's influence on cognitive decline.

In the context of AD, consistent with previous frameworks [27-29], we operationalize resilience as better-than-expected cognition in relation to pathology or higher-than-expected pathology given cognition, and resistance as absent or lower-than-expected pathology given age, genetics, disease stage, etc. We note that definitions surrounding reserve, resilience, and resistance have evolved and that investigators may subscribe to different models (e.g., [30,31]). Yet, our aim is not to adjudicate between frameworks describing these notions, but to apply the aforementioned definitions of resilience and resistance in interpreting bilingualism's effects on AD.

As a well-established factor in reducing dementia risk [16], higher education has been associated with increased Aβ deposition via positron emission tomography (PET) in MCI and AD, compared to low-educated participants matched for cognitive severity [17,18]. Sex has also been demonstrated to affect cognitive functions and reserve [16,20,21]. Women, beyond having higher dementia incidence rates [16], generally perform better on verbal tests but worse on visuospatial tasks than men in healthy populations [21]. Further, biomarker studies reveal

elevated CSF NfL levels in men relative to women across neurological conditions (e.g., AD, vascular dementia) and healthy controls [22]. Additionally, evidence suggests that sex differences in cognitive performance and biomarkers can be modulated by bilingualism [32-34].

Given the impact of these factors on cognitive decline [16-18,20-22,32-34], we hypothesize that bilingualism might interact with sex or education to confer resilience and resistance, reflected in neuropsychological and biomarker outcomes. Because participants were at the same AD biological stage (A+T+), we consider better neuropsychological performance and/or greater pathology (measured via biofluid levels) as evidence for resilience, and less pathology as evidence for resistance. Moreover, motivated by evidence that lifestyle factors influence AD pathology [16-19], we hypothesize that bilingualism-related cognitive differences may be accounted for by biological variability, and thus explore the mediating role of biomarker levels to probe potential biological pathways underlying the bilingualism-cognition link.

2 Methods

2.1 Participants

We included 567 Spanish-Catalan bilingual participants (346 female, mean age = 75.8 ± 4.59 years) from the Sant Pau Initiative on Neurodegeneration (SPIN) cohort [25] evaluated at Sant Pau Memory Unit (Barcelona, Spain). We included individuals who had a syndromic diagnosis of MCI or AD dementia, and importantly, whose CSF biomarkers supported AD pathophysiology (i.e., A+T+). According to internationally accepted clinical criteria (see full details in [25]), participants were diagnosed with MCI if their Mini–Mental State Examination (MMSE [35]) score is between 24-30, Clinical Dementia Rating (CDR) [36] global score is 0.5, and impaired cognitive performance (defined as <1.5 standard deviation on age- and education-adjusted normative scores) in at least one cognitive domain; participants were diagnosed with

AD dementia if their CDR global score is ≥ 0.5. Across participants, the age at symptom onset was 65 years and above. Participants underwent neuropsychological evaluation and provided CSF and plasma samples.

Consistent with previous research in Spanish-Catalan bilinguals in Barcelona [37-39], participants were categorized as active or passive bilinguals based on self-reported language background. During the clinical visit, participants reported their first language(s) (L1) and their preferred language for neuropsychological testing, which were used to determine the language of assessment. Prior research has found no effect for language of testing in Spanish-Catalan bilinguals in Barcelona [40] (which may, in part, be driven by typological similarity). Individuals reporting Spanish as their sole L1 were classified as passive bilinguals and were tested in Spanish, reflecting active use of Spanish with passive exposure to Catalan through immersion in the local sociolinguistic environment. Individuals reporting Catalan as L1, or both Spanish and Catalan as L1s, were classified as active bilinguals and were tested in either Spanish or Catalan according to their stated preference, reflecting early acquisition and sustained use of both languages.

This classification reflects current functional language use at the time of assessment, rather than dynamic language use across the lifespan or formal proficiency scores, which were not available for this historical cohort. In the Barcelona sociolinguistic context, Spanish and Catalan are both official languages and are used extensively across education, public administration, media, and everyday social interactions, resulting in widespread exposure to both languages. Therefore, this classification represents a coarse, ecologically grounded proxy of bilingual language use/exposure instead of a comprehensive characterization of bilingual experience. Participants with L1s other than Spanish and/or Catalan were excluded from the

present analyses. Prior studies have shown that active use vs. passive exposure is a meaningful distinction when examining bilingual language processing and cognitive outcomes in this population, though methods for determining the exact grouping varies across studies [37,39].

Based on this classification, our sample comprised 280 active bilinguals (166 female, mean age = 76 ± 4.69 years) and 287 passive bilinguals (180 female, mean age = 75.5 ± 4.48 years). All participants were recruited from Barcelona and spoke Castilian Spanish. Individuals from other regions of Spain or outside Spain were excluded to minimize variability related to different Spanish dialects, language varieties, and sociolinguistic backgrounds. This strategy resulted in a relatively homogeneous sample and reduced the impact of potential confounding factors such as significant sociocultural differences and cross-country immigration [41,42]. All procedures were approved by the ethics committee of Hospital Sant Pau and conducted in accordance with the standards for medical research involving human participants as outlined in the Declaration of Helsinki. All participants or their legally authorized representative provided written informed consent before enrollment.

2.2 Neuropsychological evaluation

Participants completed a comprehensive evaluation of neuropsychological functioning (see [25] for details). The assessment included global cognition (via MMSE), verbal memory (via Free and Cued Selective Reminding Test or FCSRT [43] immediate and delayed free and cued recall), visual memory (via geometric figures recall from the Consortium to Establish a Registry for Alzheimer's Disease or CERAD [44]), attention/executive functions (EF; via Trail-Making Test or TMT Parts A and B [45], and Wechsler Adult Intelligence Scale digit span backwards [45]), language (via phonemic and semantic fluency tasks [46], and Boston Naming Test or BNT [47]), visuospatial/visuomotor/visuoperceptive functioning (via geometric figures

copy subtest of CERAD, number location subtest from the Visual Object Space and Perception or VOSP battery [48], and Poppelreuter overlapping figures test [49]), and neuropsychiatric symptoms (via neuropsychiatric inventory [50] and Geriatric Depression Scale [51]). Note that neuropsychological performance was analyzed using individual test scores (rather than composite scores) to preserve domain- and test-specific variability. Specific to the BNT, we used the percentage of correctly named objects to accommodate the administration of the short 15-item or full 60-item version across participants. Responses provided in a language other than the test administration language were generally accepted when clearly correct; such instances were rare and were not expected to meaningfully affect performance estimates. Irrespective of language of assessment, we used the normative data from the Spanish Multicenter Normative Studies (NEURONORMA project) [52].

2.3 CSF and blood collection and analysis

CSF was obtained by lumbar puncture and collected in polypropylene tubes following international recommendations [53]. CSF levels of core AD biomarkers (Aβ-42, Aβ-40, phosphorylated tau or p-tau 181, and t-tau) were measured in the fully-automated platform Lumipulse using commercially available kits (Fujirebio Europe, Ghent, Belgium), as previously described [54]. Levels of NfL and Chitinase-3-like protein 1 (YKL-40) in CSF were measured by enzyme-linked immunosorbent assay (ELISA), and GFAP by single molecule array (Simoa) according to previously reported methods [55,56].

Blood was collected at the time of lumbar puncture, and plasma was aliquoted in polypropylene tubes. Plasma p-tau 181 and 217 samples were measured in the Lumipulse fully-automated platform with commercially available kits (Fujirebio Europe, Ghent, Belgium), as

previously described [57]. Levels of NfL and GFAP were measured using Simoa and following the manufacturer's instructions [58].

We used three CSF measures—Aβ-42, Aβ-42/40 ratio, and p-tau 181—to confirm that participants were at the A+T+ biological stage. Positivity was defined using the following cutoff values, established in prior work [25,54]: Aβ-42 ≤ 916 pg/ml, Aβ-42/40 ratio ≤ .062, and p-tau 181 ≥ 63 pg/ml. In the biomarker analysis reported below, we included CSF and plasma measures that reflect AD-specific pathophysiology (amyloidosis: Aβ-42, Aβ-40, and Aβ-42/40 ratio; tau accumulation: p-tau and t-tau), non-specific neurodegeneration (NfL), and neuroinflammation (GFAP and YKL-40). Of note, Aβ, t-tau, and YKL-40 were represented in CSF only.

2.4 Statistical modeling and analysis

We performed all statistical analyses in *R* (version 4.4.2) [59]. To address the influence of bilingualism on neuropsychological performance, we treated test outcome as count data and checked under-/over-dispersion (via the "AER" package, version 1.2-14 [60]) and excessive zeros. For neuropsychological variables that were normally dispersed, we built Poisson generalized linear models (GLMs). For variables that were under-/over-dispersed, we built negative binomial GLMs via the "MASS" package (version 7.3-65) [61], or zero-inflated negative binomial models via the "pscl" package (version 1.5.9) [62] if there were excessive zeros (over 20% of all data points). Accounting for the covariate of age, we assessed the following effects of interest: the interaction between bilingual status and education (bilingual status × education), the interaction between bilingual status and sex (bilingual status × sex), as well as bilingual status alone. To evaluate whether inclusion of a component (i.e., bilingual status or its relevant interaction) led to a significant improvement of the model, likelihood ratio tests

were conducted to compare the "full" model to a "reduced" model that did not include the component. A significant difference between the "full" and "reduced" model, as suggested by the *p*-value below .05, indicates that the assessed component has a significant effect on the neuropsychological outcome. Effect size for likelihood ratio tests was quantified using Cohen's w, computed as the square root of the likelihood-ratio χ^2 statistic (i.e., the difference in residual deviance or log-likelihoods between compared models) divided by the number of observations. Exponentiated coefficients from Poisson and negative binomial GLMs were reported as incidence rate ratios (IRRs). Analyses were conducted separately for each neuropsychological variable. Estimation of the marginal means and post hoc pairwise comparisons were implemented using the "emmeans" package (version 1.11.1) [63]. Multiple comparisons were corrected using the Bonferroni procedure, and associated effect sizes were expressed as IRRs.

Further, to address the influence of bilingualism on biomarker levels, we treated biofluid measures as continuous data and built Gamma GLMs with the log link. We evaluated the same effects of interest (i.e., bilingual status alongside its interaction with education or sex) as described in the neuropsychological analyses, while controlling for more covariates, including age, MMSE score (a proxy of overall cognitive impairment), and apolipoprotein E4 (*APOE*-4) status (considered for Aβ-related biomarkers). Following the model comparison approach described above, we analyzed the effects of bilingualism and relevant interactions on each biomarker variable. Effect size for likelihood ratio tests was reported as Cohen's w, and exponentiated coefficients were reported as rate ratios.

Lastly, to explore if the relationship between bilingualism and neuropsychological performance was mediated by biomarker levels, we performed mediation analyses via the "mediation" package (version 4.5.0) [64]. Variables included in the mediation analyses were

selected based on significant associations with bilingualism observed in the prior neuropsychological and biomarker analyses, reflecting an exploratory approach rather than a predefined mechanistic model. Mediation was evaluated by estimating the indirect effect, without requiring the independent significance of all constituent paths. Importantly, based on the subset of participants with available data for the included biomarkers, we re-assessed the associations between bilingualism and neuropsychological variables via GLMs, and only those that remained significant entered the subsequent mediation analysis. More specifically, we first fitted the mediator model where the target biomarker (the mediator) was modeled as a function of bilingual status (the treatment), and then built the outcome model where the survived neuropsychological variable (the outcome) was modeled as a function of bilingual status and the biomarker. Both models were implemented via GLMs and included the same covariates as in the primary analyses (e.g., sex, age, education, and MMSE). We computed the average causal mediation effect (ACME, i.e., the indirect effect), average direct effect (ADE), and total effect, and calculated confidence intervals (CIs) with 1000 bootstrapping samples.

3 Results

3.1 Demographic and clinical characteristics

The two language groups had comparable age and sex distribution (see Table 1). In terms of educational attainment, active bilinguals had a significantly greater number of years of education than passive bilinguals (Wilcoxon rank sum test, $p < .001$, rank-biserial $r = .17$). To account for it, we included education in the subsequent modeling analyses. Additionally, groups did not differ in the proportion of participants classified as MCI vs. AD dementia (based on Global Deterioration Scale criteria) or in *APOE*-4 carrier distribution.

3.2 Neuropsychological functioning

Accounting for age, sex, and education, we did not observe significant bilingualism effects on overall cognitive status, as indexed by MMSE scores. However, accounting for the same covariates, active bilingualism was significantly associated with better performance on a variety of neuropsychological measures across cognitive domains. In the attention/EF domain, model comparisons revealed significant effects of bilingual status on TMT-A (χ^2(1, N = 530) = 15.2, p < .001, Cohen's w = .17) and TMT-B (χ^2(1, N = 530) = 7.17, p = .007, Cohen's w = .12). According to the optimal model summaries (see supplementary Tables 1-2), bilinguals achieved significantly faster responses in both parts than passive bilinguals (Figure 1A-B). Similarly, in the language domain, we found significant bilingual status effects on BNT (χ^2(1, N = 480) = 4.22, p = .04, Cohen's w = .09) and phonemic fluency (χ^2(1, N = 536) = 4.02, p = .045, Cohen's w = .09), with active bilinguals producing significantly more accurate responses or more items (see optimal model summaries in supplementary Tables 3-4; Figure 1C-D). As to visuospatial/visuomotor functioning, we first observed a significant effect of bilingual status on CERAD figures copy (χ^2(1, N = 463) = 8.27, p = .004, Cohen's w = .13), in which active bilinguals outperformed passive bilinguals (see supplementary Table 5 and Figure 1E). We also found a significant interaction between bilingual status and sex predicting VOSP number location performance (χ^2(1, N = 526) = 4.59, p = .032, Cohen's w = .09). Based on the optimal model (see summary in supplementary Table 6), pairwise comparisons demonstrated that active bilinguals had significantly higher scores than passive bilinguals within female participants only (IRR = .88, adjusted p = .01; see Figure 1F), and male participants outperformed their female peers across language groups (passive bilingual: IRR = 1.3, adjusted p < .001; active bilingual: IRR = 1.12, adjusted p = .034). There were no significant bilingualism effects on overall cognitive status, as indexed by MMSE scores, and other neuropsychological variables (see

details in supplementary Table 7), including no instances in which active bilingualism was associated with worse performance of any neuropsychological measures.

3.3 CSF and plasma biomarkers

Controlling for age and cognitive impairment, we found various associations indicative of a "reduced pathological" biomarker profile in active bilinguals and therefore of resistance to AD-specific pathophysiologic processes and neuroinflammation. First, we found a significant interaction between bilingual status and sex on the CSF Aβ-42/40 ratio ($\chi^2(1, N = 446) = .23, p = .011$, Cohen's w = .02). Based on the optimal model (see supplementary Table 8), pairwise comparisons revealed a significantly higher Aβ-42/40 ratio—indicating reduced amyloid burden—in active compared to passive bilinguals in male participants (rate ratio = .94, adjusted $p = .044$; Figure 2A). Regarding neuroinflammation biomarkers, we found a significant interaction between bilingual status and sex that influenced CSF YKL-40 ($\chi^2(1, N = 130) = .27, p = .019$, Cohen's w = .05; see optimal model in supplementary Table 9), revealing that female participants in the active bilingual group exhibited significantly lower CSF YKL-40 levels, indicative of decreased neuroinflammation, compared to passive bilinguals (rate ratio = 1.15, adjusted $p = .018$; Figure 2B). Lastly, we observed a significant interaction effect between bilingual status and education on CSF GFAP ($\chi^2(1, N = 59) = 2.65, p = .014$, Cohen's w = .21; supplementary Table 10), with lower levels of CSF GFAP in active bilinguals being associated with a greater number of years of education (Figure 2C).

We also found two associations indicative of an "increased pathological" biomarker profile in active bilinguals, while controlling for age and cognitive impairment, and therefore provide evidence of resilience. First, we observed a significant effect of bilingual status on plasma GFAP ($\chi^2(1, N = 69) = .8, p = .024$, Cohen's w = .11; supplementary Table 11), where

active bilinguals had significantly higher levels than passive bilinguals (Figure 2D). In addition, an interaction between bilingual status and sex significantly influenced CSF Aβ-42 ($\chi^2(1, N = 446) = .37$, $p = .029$, Cohen's w = .03; supplementary Table 12). Among passive bilinguals, male participants had significantly lower Aβ-42 levels than their female counterparts (rate ratio = .9, adjusted $p = .018$; Figure 2E). We did not find significant bilingualism effects on other CSF and plasma biomarkers (see details in supplementary Table 13).

3.4 Mediation analysis of bilingualism's protective associations with neuropsychological functioning

Considering only the "protective" associations that showed more favorable profiles among active bilinguals identified in the GLM analyses, we focused on the three CSF biomarkers: Aβ-42/40 ratio, YKL-40, and GFAP. To examine whether these biomarkers mediate the relationship between bilingualism and neuropsychological functioning, we re-evaluated the associations between bilingual status and neuropsychological outcomes based on the subset of participants with available data for the three biomarkers mentioned above (see Table 2). Eight neuropsychological measures remained significantly associated, which were thus used as the outcome variables in the mediation analyses. However, as shown in Figure 3, none of the CSF biomarkers significantly mediated the relationship between active bilingual status and improved neuropsychological performance across cognitive domains: attention/EF (i.e., TMT-A and TMT-B), language (i.e., phonemic fluency), and visuospatial/visuomotor functioning (i.e., CERAD figures copy).

4 Discussion

In this study, we investigated bilingualism's impact on neuropsychological and biomarker profiles in a cohort with biomarker-confirmed AD. Since most of the available

evidence does not include pathophysiologic biomarkers, we aimed to confirm or disprove bilingualism's protective effects in an AD cohort with biomarker-confirmed diagnosis and examine its underlying molecular bases within the resilience-resistance framework. To do this, we first compared neuropsychological test performance and fluid biomarker concentrations in active vs. passive bilinguals and then conducted mediation analyses on all the favorable associations identified in the initial analysis. We found that active use of two languages was linked to better cognitive outcomes across certain but not all domains (attention/EF, language, visuospatial/visuomotor), demonstrating resilience to neurodegenerative pathophysiologic mechanisms. Further, it was associated with more favorable CSF biomarker profiles (Aβ-42/40 ratio, YKL-40, GFAP) when accounting for interactions with sex or education and controlling for age and cognitive impairment, indicating resistance to underlying pathological processes. These findings suggest that bilingualism may protect against cognitive decline through both resilience and resistance mechanisms.

4.1 Effects of bilingualism on neuropsychological functioning

We observed that independent of age and education, active bilinguals outperformed passive bilinguals on tests assessing attention/EF (TMT-A, TMT-B), language (BNT, phonemic fluency), and visuospatial/visuomotor functioning (CERAD figures copy and VOSP number location, the latter in female participants only). This result provides evidence for resilience [27-29], given the absence of significant differences in age, AD biological stage, and clinical stage between groups. Yet, previous research on these cognitive measures yields mixed findings, likely due to variability in sample characteristics, disease stage, and control of confounders.

For EF, prior studies in clinically diagnosed AD individuals often found no differences in TMT performance between language groups, for example, when comparing English

monolinguals with Welsh-English bilinguals [65] or with English bilinguals from diverse language backgrounds [66]. In contrast, studies in healthy aging populations have reported bilingual advantages. Ihle et al [67] identified a positive relationship between the number of languages spoken and processing speed (TMT-A) among Swiss participants, though only when education and occupation were not controlled. Accounting for these variables, Estanga et al [23] found that relative to monolinguals, late bilinguals performed better on TMT-B and early bilinguals on digits backward. Conversely, Massa et al [68] reported a monolingual advantage in older French speakers, who showed less interference (i.e., smaller B-A difference in response times or RT) when switching between the letter and number conditions than their French-Italian bilingual peers. However, focusing on healthy individuals and those with MCI or AD from the same Spanish-Catalan bilingual population studied here, Calabria et al [37] found that bilingualism—measured as a composite of language proficiency, exposure, and use—was associated with better conflict resolution (i.e., smaller RT differences between incongruent and congruent trials) on a spatial Stroop task. This finding aligns with our result that active bilingualism contributes to better EF, especially given our relatively homogeneous sample.

In the language domain, our results lend further support to the link between bilingualism and better phonemic fluency, consistent with prior findings in healthy bilinguals from the Spanish-Catalan population [69] and from other sociolinguistic contexts, including Canada [70], France [68], India [4], and Sweden [71]. This positive effect likely reflects EF processes underpinning phonemic fluency, which are enhanced in bilinguals [72]. Importantly, our findings extend this pattern to individuals with biomarker-confirmed AD, demonstrating that it persists in pathological aging. Nonetheless, some studies in AD populations without biomarker confirmation report mixed or negative effects. For example, Anderson et al [66] found lower

letter fluency scores in English-speaking bilinguals with probable AD than their monolingual peers, whereas Clare et al [65] observed no group differences in letter fluency or BNT in a Welsh AD cohort. In comparison, a bilingual disadvantage in semantic fluency and BNT is often reported in the literature, possibly due to cross-language interference and reduced vocabulary in bilinguals [71]. However, these studies usually test the less dominant language and focus on healthy younger participants [72,73], differing from our sample and others documenting more favorable performance in bilinguals.

As for visuospatial/visuomotor skills, we observed superior performance on the CERAD figures copy test in active bilinguals. This aligns with Perani et al [74], who showed better visuospatial short-term memory in German-Italian bilinguals with early-stage AD compared with Italian monolinguals. Similar findings have been reported in healthy bilinguals. For example, Estanga et al [23] found that both early and late bilinguals outperformed monolinguals on the Judgement of Line Orientation Test. McLeay [75] found faster mental rotation performance in Welsh-English bilinguals than in monolinguals. We also replicated the well-documented sex difference in visuospatial ability [21,76], with men outperforming women on VOSP number location across language groups. Notably, the bilingual benefit was evident only in women, which echoes prior findings that bilingualism may modulate sex differences in cognitive performance [32,33].

4.2 Effects of bilingualism on biofluid markers of brain health

Importantly, fluid biomarkers reflect underlying pathophysiological processes rather than functional brain status or neural plasticity per se. Our analyses revealed multiple interactions between bilingualism and sex or education on Aβ deposition and neuroinflammation biomarkers. Active bilinguals exhibited a more favorable CSF profile—indicating less pathology and thus

resistance [27-29]—with a higher Aβ-42/40 ratio in male participants, lower YKL-40 in female participants, and lower GFAP in individuals with higher education, when compared to passive bilinguals. No bilingualism effects emerged for CSF tau or neurodegeneration markers (p-tau, t-tau, and NfL). Our results differ from those of Estanga et al [23], who studied cognitively healthy adults (aged 40–80 years) and found lower CSF t-tau levels in early bilinguals relative to monolinguals.

Active bilinguals also showed greater pathology—demonstrating resilience [27-29]—with higher plasma GFAP across sexes. Although we did not examine education effects independently on Aβ deposition, prior PET evidence has linked higher education to increased Aβ accumulation in AD individuals matched for cognitive severity [17], suggesting that education and bilingualism may both confer protection through resilience. Interestingly, CSF and plasma GFAP were associated with different "protective" effects (i.e., resilience-resistance) while putatively measuring the same pathophysiologic process. We suspect this may reflect temporal dynamics of AD pathophysiology, as plasma GFAP levels are higher than those of CSF in preclinical and symptomatic stages [77].

4.3 Mediation effects of biomarkers on the relationship between bilingualism and neuropsychological functioning

Given prior evidence linking active bilingualism to better cognitive performance, we examined whether this association was mediated by a beneficial effect consisting in the attenuation of AD-specific or general pathophysiologic mechanisms involved in neurodegeneration, as reflected in fluid biomarker levels. However, none of the examined biomarkers showed a significant mediation effect. Given the exploratory nature of these analyses and the cross-sectional design, this finding suggests the absence of a detectable indirect effect in

the sample, rather than evidence against a biological contribution to bilingualism-related cognitive differences. It is also possible that unmeasured physiologic mechanisms such as markers of synaptic health or function and brain imaging, or links between biofluid and structural brain measures may underlie the observed bilingual cognitive advantages. Only one prior study (Estanga et al. [23]) investigated whether bilingualism moderated CSF biomarker-cognition relations in healthy older adults, and similarly found no significant effects. These findings underscore the need for continued research on the complex interplay among bilingualism, biomarkers, and cognitive aging. Despite these null results, bilingualism, as an environmental enrichment form, has been postulated to enhance neurogenesis and synaptogenesis via multiple neural factors [78]. For example, vascular endothelial growth factor levels increase with high-intensity hippocampal-dependent cognitive activity like speaking two languages [78]. Brain-derived neurotropic factor, which supports synaptic plasticity and is reduced in AD brains, can be modulated by bilingual experience too [78]. These mechanisms overlap with those engaged by physical activity in mitigating cognitive decline [79], suggesting bilingualism may represent another cost-effective approach to maintaining brain health.

4.4 Limitations and future directions

Following prior work, we operationalized bilingualism by comparing active vs. passive bilinguals. We acknowledge that this approach represents a limitation of the present study, as it was constrained by data availability in this historical cohort and does not capture the full multidimensional nature of bilingual experience. Nonetheless, our findings remain relevant to other passive bilingual communities where exposure to additional languages does not necessarily imply speaking proficiency. Crucially, meaningful comparisons along the mono-bilingualism continuum depend on sociocultural contexts; only by sampling along this continuum can we gain

a holistic picture of bilingualism's effects. Moreover, the cross-sectional design of the present study limits inferences about the temporal dynamics underlying resilience and resistance, particularly with respect to whether bilingualism is associated with trajectories of biomarker change over time or reflects interindividual differences at disease onset.

Future work should examine more nuanced bilingual characteristics (e.g., age of acquisition or AoA, language dominance, proficiency), which may uncover additional relations of interest. For instance, incorporating AoA might identify subgroup-specific effects, such as differences between early and late bilinguals observed by Estanga et al [23]. Further, accounting for more fine-grained socioeconomic indicators (e.g., income, occupational complexity) in future investigations may help disentangle bilingualism-related effects from broader life-course factors, while longitudinal designs will be necessary to more directly examine the causal pathways linking bilingualism to cognitive and biomarker outcomes.

4.5. Conclusion

This study demonstrates the protective effects of active bilingualism in older adults with biomarker-confirmed AD. Our results lend further support to bilinguals' better cognitive performance across domains (attention/EF, language, and visuospatial/visuomotor), highlighting cognitive resilience. At the biological level, we provide novel evidence of a more favorable CSF biomarker profile in active bilinguals—a higher Aβ-42/40 ratio and lower levels of neuroinflammation markers (YKL-40 and GFAP)—thereby indicating resistance. Overall, these findings suggest that bilingual experience may confer benefits through both resilience and resistance to AD pathology mechanisms.

Acknowledgements

The authors would like to thank all participants for their contribution to the research.

Sources of Funding

This work is supported by the Alzheimer's Association (AACSF-22-972945) awarded to M.A.S.-S., and R01AG080470 from the National Institute on Aging (NIA) of the National Institute of Health (NIH) awarded to S.M.G. and M.A.S.-S. M.A.S.-S. is also supported by funding from the Spanish Institute of Health Carlos III co-funded by the European Union (Juan Rodés research grant JR18-00018; Fondo de investigación sanitaria grant PI19/00882), the Department of Research and Universities from the Generalitat de Catalunya (2021 SGR 00979). J.S.-G. acknowledges support from the NIH-NIA R01AG080470 grant.

S.R.-G. reported receiving contract funding from the Alzheimer's Association (AACSF-21-850193). I.I.-G. acknowledges support from Institute of Health Carlos III (ISCIII), Spain (PI21/00791 and PI24/00598) jointly funded by Fondo Europeo de Desarrollo Regional, Unión Europea, "Una manera de hacer Europa." I.I.-G. is a senior Atlantic Fellow for Equity in Brain Health at the Global Brain Health Institute (GBHI) and receives funding from the Alzheimer's Association (AACSF-21-850193), and the Alzheimer Society (GBHI ALZ UK-21-72097). I.I.-G. was also supported by the Juan Rodés Contract (JR20/0018) from the Carlos III National Institute of Health of Spain, partly funded by the European Social Fund.

L.V.-A. was supported by Instituto de Salud Carlos III through the Sara Borrell Postdoctoral Fellowship (CD23/00235). M.C. was supported by Project PID2023-149755OB-I00, funded by the Ministry of Science and Innovation, the State Research Agency 10.13039/501100011033 and the European Regional Development Fund FEDER, EU. A.B. acknowledges support from Instituto de Salud Carlos III and co-funded by the European Union through the Miguel Servet grant (CP20/00038) and Fondo de Investigaciones Sanitario (PI22/00307), the Alzheimer's Association (AARG-22-923680), and the Ajuntament de Barcelona, in collaboration with Fundació La Caixa (23S06157-001).

Disclosures

S. R.-G. reported honoraria for educational events from Esteve Pharmaceuticals, S.A. J.A. participated in educational activities with Lilly, Esteve and Roche diagnostics.

M. C.☐I. has received personal fees for service on the advisory boards, speaker honoraria or educational activities from IMSERSO, Esteve, Lilly, Neuraxpharm, Adium Pharma, and Roche.

I. I.-G. participated in advisory boards from UCB and Nutricia, and received speaker honoraria from Almirall, Esteve Pharmaceuticals S.A, Kern Pharma, Krka Farmacéutica S.L., Lilly, Nutricia, and Zambon S.A.U.

J. F. reported serving on the advisory boards, adjudication committees, or speaker honoraria from AC Immune, Adamed, Alzheon, Biogen, Eisai, Esteve, Fujirebio, Ionis, Laboratorios Carnot, Life Molecular Imaging, Lilly, Novo Nordisk, Perha, Roche, Zambón. JF reports holding a patent for markers of synaptopathy in neurodegenerative disease (licensed to ADx, WO2019175379).

O. B. reports holding a patent for markers of synaptopathy in neurodegenerative disease (licensed to ADx NeuroSciences N.V., WO2019175379 Markers of synaptopathy in neurodegenerative diseases).

D. A. participated in advisory boards from Fujirebio-Europe, Roche Diagnostics, Grifols S.A., Schwabe and Lilly, and received speaker honoraria from Fujirebio-Europe, Roche Diagnostics, Nutricia, Krka Farmacéutica S.L., Zambon S.A.U., Neuraxpharm, Alter Medica, Lilly and Esteve Pharmaceuticals S.A. DA declares holding a patent for markers of synaptopathy in neurodegenerative disease (licensed to ADx NeuroSciences N.V., WO2019175379 Markers of synaptopathy in neurodegenerative diseases).

The remaining authors declare no conflicts of interest.

References

[1]. Celik S, Kokje E, Meyer P, Frölich L, Teichmann B. Does bilingualism influence neuropsychological test performance in older adults? A systematic review. *Appl Neuropsychol Adult*. 2020;29(4):855-873. doi:10.1080/23279095.2020.1788032

[2]. Anderson JAE, Hawrylewicz K, Grundy JG. Does bilingualism protect against dementia? A meta-analysis. *Psychon Bull Rev*. 2020;27(5):952-965. doi:10.3758/s13423-020-01736-5

[3]. de Leon J, Grasso SM, Welch A, et al. Effects of bilingualism on age at onset in two clinical Alzheimer's disease variants. *Alzheimers Dement*. 2020;16(12):1704-1713. doi:10.1002/alz.12170

[4]. Venugopal A, Paplikar A, Varghese FA, et al. Protective effect of bilingualism on aging, MCI, and dementia: A community-based study. *Alzheimers Dement*. 2024;20(4):2620-2631. doi:10.1002/alz.13702

[5]. Alladi S, Bak TH, Duggirala V, et al. Bilingualism delays age at onset of dementia, independent of education and immigration status. *Neurology*. 2013;81(22):1938-1944. doi:10.1212/01.wnl.0000436620.33155.a4

[6]. Sala A, Malpetti M, Farsad M, et al. Lifelong bilingualism and mechanisms of neuroprotection in Alzheimer dementia. *Hum Brain Mapp*. 2022;43(2):581-592.

doi:10.1002/hbm.25605

[7]. von Bastian CC, Souza AS, Gade M. No evidence for bilingual cognitive advantages: A test of four hypotheses. *J Exp Psychol Gen*. 2016;145(2):246-258. doi:10.1037/xge0000120

[8]. Tao L, Taft M, Gollan TH. The bilingual switching advantage: Sometimes related to bilingual proficiency, sometimes not. *J Int Neuropsychol Soc*. 2015;21(7):531-544. doi:10.1017/S1355617715000521

[9]. Pelham SD, Abrams L. Cognitive advantages and disadvantages in early and late bilinguals. *J Exp Psychol Learn Mem Cogn*. 2014;40(2):313-325. doi:10.1037/a0035224

[10]. Prior A, Macwhinney B. A bilingual advantage in task switching. *Biling (Camb Engl)*. 2010;13(2):253-262. doi:10.1017/S1366728909990526

[11]. van den Noort M, Struys E, Bosch P, et al. Does the bilingual advantage in cognitive control exist and if so, what are its modulating factors? A systematic review. *Behav Sci (Basel)*. 2019;9(3):27. Published 2019 Mar 13. doi:10.3390/bs9030027

[12]. Abutalebi J, Canini M, Della Rosa PA, Sheung LP, Green DW, Weekes BS. Bilingualism protects anterior temporal lobe integrity in aging. *Neurobiol Aging*. 2014;35(9):2126-2133. doi:10.1016/j.neurobiolaging.2014.03.010

[13]. van den Noort M, Vermeire K, Bosch P, et al. A systematic review on the possible relationship between bilingualism, cognitive decline, and the onset of dementia. *Behavioral Sciences*. 2019;9(7). doi:10.3390/bs9070081

[14]. Brini S, Sohrabi HR, Hebert JJ, et al. Bilingualism is associated with a delayed onset of dementia but not with a lower risk of developing it: A systematic review with meta-analyses. *Neuropsychology Review*. 2020;30(1):1-24. doi:10.1007/s11065-020-09426-8

[15]. Beach TG, Monsell SE, Phillips LE, Kukull W. Accuracy of the clinical diagnosis of

Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005-2010. *J Neuropathol Exp Neurol*. 2012;71(4):266-273. doi:10.1097/NEN.0b013e31824b211b

[16]. Livingston G, Huntley J, Liu KY, et al. Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. *Lancet*. 2024;404(10452):572-628. doi:10.1016/S0140-6736(24)01296-0

[17]. Kemppainen NM, Aalto S, Karrasch M, et al. Cognitive reserve hypothesis: Pittsburgh Compound B and fluorodeoxyglucose positron emission tomography in relation to education in mild Alzheimer's disease. *Ann Neurol*. 2008;63(1):112-118. doi:10.1002/ana.21212

[18]. Arenaza-Urquijo EM, Bejanin A, Gonneaud J, et al. Association between educational attainment and amyloid deposition across the spectrum from normal cognition to dementia: Neuroimaging evidence for protection and compensation. *Neurobiol Aging*. 2017;59:72-79. doi:10.1016/j.neurobiolaging.2017.06.016

[19]. Moniruzzaman M, Kadota A, Akash MS, et al. Effects of physical activities on dementia-related biomarkers: A systematic review of randomized controlled trials. *Alzheimers Dement (N Y)*. 2021;6(1):e12109. Published 2021 Jan 20. doi:10.1002/trc2.12109

[20]. Levine DA, Gross AL, Briceño EM, et al. Sex differences in cognitive decline among US adults. *JAMA Network Open*. 2021;4(2):e210169. doi: 10.1001/jamanetworkopen.2021.0169

[21]. Weiss EM, Kemmler G, Deisenhammer EA, Fleischhacker WWolfgang, Delazer M. Sex differences in cognitive functions. *Pers Individ Dif*. 2003;35(4):863-875. doi:10.1016/s0191-8869(02)00288-x

[22]. Bridel C, van Wieringen WN, Zetterberg H, et al. Diagnostic value of cerebrospinal fluid neurofilament light protein in neurology: A systematic review and meta-analysis. *JAMA Neurol*. 2019;76(9):1035-1048. doi:10.1001/jamaneurol.2019.1534

[23]. Estanga A, Ecay-Torres M, Ibañez A, et al. Beneficial effect of bilingualism on Alzheimer's disease CSF biomarkers and cognition. *Neurobiol Aging*. 2017;50:144-151. doi:10.1016/j.neurobiolaging.2016.10.013

[24]. Grasso SM, Clark AL, Petersen M, O'Bryant S; Health and Aging Brain Study (HABS☐HD) Study Team. Bilingual neurocognitive resiliency, vulnerability, and Alzheimer's disease biomarker correlates in Latino older adults enrolled in the Health and Aging Brain Study - Health Disparities (HABS-HD). *Alzheimers Dement (Amst)*. 2023;15(4):e12509. doi:10.1002/dad2.12509

[25]. Alcolea D, Clarimón J, Carmona-Iragui M, et al. The Sant Pau Initiative on Neurodegeneration (SPIN) cohort: A data set for biomarker discovery and validation in neurodegenerative disorders. *Alzheimers Dement (N Y)*. 2019;5:597-609. doi:10.1016/j.trci.2019.09.005

[26]. Jack CR Jr, Bennett DA, Blennow K, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. *Alzheimers Dement*. 2018;14(4):535-562. doi:10.1016/j.jalz.2018.02.018

[27]. Arenaza-Urquijo EM, Vemuri P. Resistance vs resilience to Alzheimer disease: Clarifying terminology for preclinical studies. *Neurology*. 2018;90(15):695-703. doi:10.1212/WNL.0000000000005303

[28]. Arenaza-Urquijo EM, Vemuri P. Improving the resistance and resilience framework for aging and dementia studies. *Alzheimers Res Ther*. 2020;12(1):41. doi:10.1186/s13195-020-00609-2

[29]. Montine TJ, Cholerton BA, Corrada MM, et al. Concepts for brain aging: Resistance, resilience, reserve, and compensation. *Alzheimers Res Ther*. 2019;11(1):22. doi:10.1186/s13195-

019-0479-y

[30]. Stern Y, Albert M, Barnes CA, Cabeza R, Pascual-Leone A, Rapp PR. A framework for concepts of reserve and resilience in aging. *Neurobiol Aging*. 2023;124:100-103. doi:10.1016/j.neurobiolaging.2022.10.015

[31]. Cabeza R, Albert M, Belleville S, et al. Maintenance, reserve and compensation: The cognitive neuroscience of healthy ageing. *Nat Rev Neurosci*. 2018;19(11):701-710. doi:10.1038/s41583-018-0068-2

[32]. Subramaniapillai S, Rajah MN, Pasvanis S, Titone D. Bilingual experience and executive control over the adult lifespan: The role of biological sex. *Biling (Camb Engl)*. 2018;22(04):733-751. doi:10.1017/s1366728918000317

[33]. Gonzalez-Marquez, M. Language, thought, and . . . brain? In: Spivey M, McRae K, Joanisse M, eds. *The Cambridge Handbook of Psycholinguistics*. Cambridge University Press; 2012:674-692. doi: 10.1017/CBO9781139029377.035

[34]. Calvo N, Phillips N, Bialystok E, Einstein G. Biological sex and bilingualism: Its impact on risk and resilience for dementia. *Alzheimers Dement (Amst)*. 2026;18(1):e70255. doi:10.1002/dad2.70255

[35]. Blesa R, Pujol M, Aguilar M, et al. Clinical validity of the 'mini-mental state' for Spanish speaking communities. *Neuropsychologia*. 2001;39(11):1150-1157. doi:10.1016/s0028-3932(01)00055-0

[36]. Morris JC. The Clinical Dementia Rating (CDR): Current version and scoring rules. *Neurology*. 1993;43(11):2412-2414. doi:10.1212/wnl.43.11.2412-a

[37]. Calabria M, Hernández M, Cattaneo G, et al. Active bilingualism delays the onset of mild cognitive impairment. *Neuropsychologia*. 2020;146:107528. doi:

10.1016/j.neuropsychologia.2020.107528

[38]. Cattaneo G, Costa A, Gironell A, Calabria M. On the specificity of bilingual language control: A study with Parkinson's disease patients. *Biling (Camb Engl)*. 2019;23(3):570-578. doi: 10.1017/s136672891900004x

[39]. Branzi FM, Calabria M, Gade M, Fuentes LJ, Costa A. On the bilingualism effect in task switching. *Biling (Camb Engl)*. 2016;21(1):195-208. doi: 10.1017/s136672891600119x

[40]. Alegret M, Espinosa A, Vinyes-Junqué G, et al. Normative data of a brief neuropsychological battery for Spanish individuals older than 49. *J Clin Exp Neuropsychol*. 2012;34(2):209-219. doi:10.1080/13803395.2011.630652

[41]. Fuller-Thomson E, Kuh D. The healthy migrant effect may confound the link between bilingualism and delayed onset of Alzheimer's disease. *Cortex*. 2014;52:128-130. doi:10.1016/j.cortex.2013.08.009

[42]. Smithson L, Paradis J, Nicoladis E. Bilingualism and receptive vocabulary achievement: Could sociocultural context make a difference? *Biling (Camb Engl)*. 2014;17(4):810-821. doi:10.1017/S1366728913000813

[43]. Peña-Casanova J, Gramunt-Fombuena N, Quiñones-Ubeda S, et al. Spanish Multicenter Normative Studies (NEURONORMA Project): Norms for the Rey-Osterrieth complex figure (copy and memory), and free and cued selective reminding test. *Arch Clin Neuropsychol*. 2009;24(4):371-393. doi:10.1093/arclin/acp041

[44]. Morris JC, Mohs RC, Rogers H, Fillenbaum G, Heyman A. Consortium to establish a registry for Alzheimer's disease (CERAD) clinical and neuropsychological assessment of Alzheimer's disease. *Psychopharmacol Bull*. 1988;24(4):641-652.

[45]. Peña-Casanova J, Quiñones-Ubeda S, Quintana-Aparicio M, et al. Spanish Multicenter

Normative Studies (NEURONORMA Project): Norms for verbal span, visuospatial span, letter and number sequencing, trail making test, and symbol digit modalities test. *Arch Clin Neuropsychol*. 2009;24(4):321-341. doi:10.1093/arclin/acp038

[46]. Peña-Casanova J, Quiñones-Ubeda S, Gramunt-Fombuena N, et al. Spanish Multicenter Normative Studies (NEURONORMA Project): Norms for verbal fluency tests. *Arch Clin Neuropsychol*. 2009;24(4):395-411. doi:10.1093/arclin/acp042

[47]. Peña-Casanova J, Quiñones-Ubeda S, Gramunt-Fombuena N, et al. Spanish Multicenter Normative Studies (NEURONORMA Project): Norms for Boston naming test and token test. *Arch Clin Neuropsychol*. 2009;24(4):343-354. doi:10.1093/arclin/acp039

[48]. Peña-Casanova J, Quintana-Aparicio M, Quiñones-Ubeda S, et al. Spanish Multicenter Normative Studies (NEURONORMA Project): Norms for the visual object and space perception battery-abbreviated, and judgment of line orientation. *Arch Clin Neuropsychol*. 2009;24(4):355-370. doi:10.1093/arclin/acp040

[49]. Poppelreuter W. *Die Psychischen Schäedungen durch Kopfschuss im Kriege 1914-1916*. Leipzig: Voss; 1917.

[50]. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia. *Neurology*. 1994;44(12):2308-2314. doi:10.1212/wnl.44.12.2308

[51]. Yesavage JA. Geriatric Depression Scale. *Psychopharmacol Bull*. 1988;24:709-711.

[52]. Peña-Casanova J, Blesa R, Aguilar M, et al. Spanish Multicenter Normative Studies (NEURONORMA Project): Methods and sample characteristics. *Arch Clin Neuropsychol*. 2009;24(4):307-319. doi:10.1093/arclin/acp027

[53]. Alcolea, D. et al. Feasibility of lumbar puncture in the study of cerebrospinal fluid

biomarkers for Alzheimer's disease: A multicenter study in Spain. *J. Alzheimers Dis*. 2014;39,

719-726. doi:10.3233/JAD-131334

[54]. Alcolea D, Pegueroles J, Muñoz L, et al. Agreement of amyloid PET and CSF biomarkers

for Alzheimer's disease on Lumipulse. *Ann Clin Transl Neurol*. 2019;6(9):1815-24.

doi:10.1002/acn3.50873

[55]. Illán-Gala, I. et al. CSF sAPPβ, YKL-40, and NfL along the ALS-FTD spectrum.

Neurology. 2018;91(17), e1619-e1628. doi:10.1212/WNL.0000000000006383

[56]. Montoliu-Gaya L, Alcolea D, Ashton NJ, et al. Plasma and cerebrospinal fluid glial

fibrillary acidic protein levels in adults with Down Syndrome: A longitudinal cohort study.

EBioMedicine. 2023;90:104547. doi:10.1016/j.ebiom.2023.104547

[57]. Arranz J, Zhu N, Rubio-Guerra S, et al. Diagnostic performance of plasma pTau217,

pTau181, Aβ1-42 and Aβ1-40 in the LUMIPULSE automated platform for the detection of

Alzheimer disease. *Alzheimers Res Ther*. 2024;16(1):139. doi:10.1186/s13195-024-01513-9

[58]. Alcolea D, Delaby C, Muñoz L, et al. Use of plasma biomarkers for AT(N) classification

of neurodegenerative dementias. *J Neurol Neurosurg Psychiatry*. 2021;92(11):1206-1214.

doi:10.1136/jnnp-2021-326603

[59]. R Core Team. *R: A Language and Environment for Statistical Computing*. Vienna, Austria:

R Foundation for Statistical Computing; 2024. https://www.R-project.org/

[60]. Kleiber C, Zeileis A. *Applied Econometrics with R*. Springer-Verlag;

2008. doi:10.1007/978-0-387-77318-6

[61]. Venables WN, Ripley BD. (2002). *Modern Applied Statistics with S*. 4th ed. Springer;

2002.

[62]. Zeileis A, Kleiber C, Jackman S. Regression models for count data in R. *J Stat Softw*.

2008; 27(8):1-25. doi:10.18637/jss.v027.i08

[63]. Lenth R. emmeans: Estimated Marginal Means, aka Least-Squares Means. R package version 1.11.1-00001. 2025. https://rvlenth.github.io/emmeans/

[64]. Tingley D, Yamamoto T, Hirose K, Keele L, Imai K. mediation: R package for causal mediation analysis. *J Stat Softw*. 2014;59(5):1-38. doi: 10.18637/jss.v059.i05

[65]. Clare L, Whitaker CJ, Craik FI, et al. Bilingualism, executive control, and age at diagnosis among people with early-stage Alzheimer's disease in Wales. *J Neuropsychol*. 2016;10(2):163-185. doi:10.1111/jnp.12061

[66]. Anderson JA, Saleemi S, Bialystok E. Neuropsychological assessments of cognitive aging in monolingual and bilingual older adults. *J Neurolinguistics*. 2017;43(A):17-27. doi:10.1016/j.jneuroling.2016.08.001

[67]. Ihle A, Oris M, Fagot D, Kliegel M. The relation of the number of languages spoken to performance in different cognitive abilities in old age. *J Clin Exp Neuropsychol*. 2016;38(10):1103-1114. doi:10.1080/13803395.2016.1197184

[68]. Massa E, Köpke B, El Yagoubi R. Age-related effect on language control and executive control in bilingual and monolingual speakers: Behavioral and electrophysiological evidence. *Neuropsychologia*. 2020;138:107336. doi:10.1016/j.neuropsychologia.2020.107336

[69]. Olabarrieta-Landa L, Benito-Sánchez I, Alegret M, et al. Letter verbal fluency in Spanish-, Basque-, and Catalan-speaking individuals: Does the selection of the letters influence the outcome? *J Speech Lang Hear Res*. 2019;62(7):2400-2410. doi:10.1044/2019_JSLHR-L-18-0365

[70]. Friesen DC, Luo L, Luk G, Bialystok E. Proficiency and control in verbal fluency performance across the lifespan for monolinguals and bilinguals. *Lang Cogn Neurosci*.

2015;30(3):238-250. doi:10.1080/23273798.2014.918630

[71]. Marsh JE, Hansson P, Sörman DE, Ljungberg JK. Executive processes underpin the bilingual advantage on phonemic fluency: Evidence from analyses of switching and clustering. *Front Psychol*. 2019;10:1355. doi:10.3389/fpsyg.2019.01355

[72]. Roberts PM, Garcia LJ, Desrochers A, Hernandez D. English performance of proficient bilingual adults on the Boston Naming Test. *Aphasiology*. 2002;16(4-6):635-645. doi: 10.1080/02687030244000220

[73]. Portocarrero JS, Burright RG, Donovick PJ. Vocabulary and verbal fluency of bilingual and monolingual college students. *Arch Clin Neuropsychol*. 2007;22(3):415-422. doi:10.1016/j.acn.2007.01.015

[74]. Perani D, Farsad M, Ballarini T, et al. The impact of bilingualism on brain reserve and metabolic connectivity in Alzheimer's dementia. *Proc Natl Acad Sci U S A*. 2017;114(7):1690-1695. doi:10.1073/pnas.1610909114

[75]. McLeay H. The relationship between bilingualism and the performance of spatial tasks. *Int J Biling Educ Biling*. 2003;6(6):423-438. doi:10.1080/13670050308667795

[76]. Resnick SM. Sex differences in mental rotations: An effect of time limits? *Brain Cogn*. 1993;21(1):71-79. doi:10.1006/brcg.1993.1005

[77]. Benedet AL, Milà-Alomà M, Vrillon A, et al. Differences between plasma and cerebrospinal fluid glial fibrillary acidic protein levels across the Alzheimer disease continuum. *JAMA Neurol*. 2021;78(12):1471-1483. doi:10.1001/jamaneurol.2021.3671

[78]. Kim S, Jeon SG, Nam Y, Kim HS, Yoo DH, Moon M. Bilingualism for dementia: Neurological mechanisms associated with functional and structural changes in the brain. *Front Neurosci*. 2019;13:1224. doi:10.3389/fnins.2019.01224

[79]. Lista I, Sorrentino G. Biological mechanisms of physical activity in preventing cognitive decline. *Cell Mol Neurobiol*. 2010;30(4):493-503. doi:10.1007/s10571-009-9488-x

Table 1. Descriptive statistics of demographic, clinical, neuropsychological, and biomarker data across passive and active bilingual groups

Variable	Passive bilingual (*N* = 287)	Active bilingual (*N* = 280)	*N*
Age (in years)	75.5 (4.48)	76.0 (4.69)	567
Male/Female	107/180	113/166	566
Education (in years)	9.71 (5)	11.2 (4.45)	549
MCI/AD dementia	190/97	188/92	567
APOE-4 carrier (one or two allele)	141 (49.1%)	132 (47.1%)	273
Neuropsychological functioning			
MMSE	24.1 (3.65)	24.9 (3.32)	492
FCSRT immediate free recall	6.56 (6.31)	6.29 (6.1)	530
FCSRT immediate cued recall	18.8 (12.7)	18.5 (12.6)	530
FCSRT delayed free recall	1.86 (2.69)	1.58 (2.49)	530
FCSRT delayed cued recall	6.15 (4.93)	5.82 (4.77)	528
CERAD figures free recall	2.16 (2.85)	2.04 (2.76)	464
Trail Making Test-A (in seconds)	98.5 (39.9)	81.9 (37.7)	531
Trail Making Test-B (in seconds)	267 (64.5)	243 (75.7)	531

Digit span backwards	3.18 (1)	3.45 (0.99)	535
Boston Naming Test (in percentage)	66.4 (15.7)	70.1 (15.5)	480
Phonemic fluency	8.11 (4.24)	9.19 (4.54)	537
Semantic fluency	11.2 (4.41)	11.8 (4.95)	537
CERAD figures copy	8.31 (2.26)	9.29 (1.79)	463
Poppelreuter overlapping figures	8.98 (1.28)	9.34 (1.11)	533
VOSP number location	6.3 (2.92)	6.97 (2.55)	527
Neuropsychiatric inventory	11.7 (14.4)	9.86 (11.1)	400
Geriatric depression scale	9.82 (6.26)	9.44 (5.5)	529
CSF and plasma biomarker			
CSF Aβ-42 (pg/mL)	580 (184)	562 (163)	528
CSF Aβ-40 (pg/mL)	13,334 (4094)	12,737 (3449)	528
CSF Aβ-42/40 ratio	0.044 (0.009)	0.045 (0.008)	528
CSF p-tau 181 (pg/mL)	118 (61.6)	119 (58.6)	528
Plasma p-tau 181 (pg/mL)	21 (10.2)	20.4 (8.49)	85
Plasma p-tau 217 (pg/mL)	1.24 (0.56)	1.47 (0.76)	69
CSF t-tau (pg/mL)	726 (332)	726 (331)	527
CSF NfL (pg/mL)	1095 (678)	1171 (783)	128
Plasma NfL (pg/mL)	19.5 (12.5)	18.2 (8.86)	173
CSF GFAP (pg/mL)	10,779 (6573)	9693 (6611)	59
Plasma GFAP (pg/mL)	228 (79.3)	282 (133)	69
CSF YKL-40 (pg/mL)	308 (67.9)	305 (108)	131

NOTE. Variables in bold indicate significant group comparisons (i.e., $p < 0.05$) derived from Wilcoxon rank-sum or Chi-squared tests (demographic and clinical variables) and from main effects of bilingual status observed in generalized linear model analyses (neuropsychological and biomarker variables). Mean

(standard deviation) and quantity (frequency in %) are presented for continuous variables and categorical variables, respectively.

Abbreviations: MCI: mild cognitive impairment. AD: Alzheimer's disease. *APOE*: Apolipoprotein E. MMSE: Mini-Mental State Examination. FCSRT: Free and Cued Selective Reminding Test. CERAD: Consortium to Establish a Registry for Alzheimer's Disease. VOSP: Visual Object Space and Perception. CSF: cerebrospinal fluid. Aβ: Amyloid-beta. p-tau: phosphorylated tau. t-tau: total tau. NfL: neurofilament light. GFAP: glial fibrillary acidic protein. YKL-40: Chitinase-3-like protein 1 (CHI3L1, also known as YKL-40).

Table 2. Associations between bilingual status and neuropsychological outcomes in the subset of participants with biomarker data showing favorable profiles in active bilinguals

Biomarker	Neuropsychological outcome	Association between bilingual status and neuropsychological outcome
CSF Aβ-42/40 ratio	TMT-A	$p < .001$ ($\chi^2(1, N = 438) = 15.18$, Cohen's w = .19) ***
	TMT-B	$p = .019$ ($\chi^2(1, N = 438) = 5.54$, Cohen's w = .11) *
	BNT	$p = 0.19$ ($\chi^2(1, N = 438) = 1.72$, Cohen's w = .06)
	Phonemic Fluency	$p = .041$ ($\chi^2(1, N = 442) = 4.17$, Cohen's w = .1) *
	CERAD Figures Copy	$p = .022$ ($\chi^2(1, N = 423) = 5.23$, Cohen's w = .11) *
CSF YKL-40	TMT-A	$p = .006$ ($\chi^2(1, N = 128) = 7.63$, Cohen's w = .24) **
	TMT-B	$p = .019$ ($\chi^2(1, N = 128) = 5.47$, Cohen's w = .21) *
	BNT	$p = .337$ ($\chi^2(1, N = 128) = 1.28$, Cohen's w = .1)
	Phonemic Fluency	$p = .444$ ($\chi^2(1, N = 130) = .59$, Cohen's w = .07)
	CERAD Figures Copy	$p = .103$ ($\chi^2(1, N = 123) = 2.66$, Cohen's w = .15)

	TMT-A	$p = .002$ (χ^2(1, $N = 58$) = 9.74, Cohen's w = .41) **
	TMT-B	$p = .065$ (χ^2(1, $N = 58$) = 3.4, Cohen's w = .24)
CSF GFAP	BNT	$p = .166$ (χ^2(1, $N = 58$) = .51, Cohen's w = .09)
	Phonemic Fluency	$p = .114$ (χ^2(1, $N = 58$) = 2.49, Cohen's w = .21)
	CERAD Figures Copy	$p = .02$ (χ^2(1, $N = 57$) = 5.45, Cohen's w = .31) *

NOTE. Consistent with the primary neuropsychological analyses, all models were adjusted for age, sex, and education. Associations between bilingual status and neuropsychological outcomes that remained significant ($p < .05$) were retained for subsequent mediation analyses. *P*-values were derived from likelihood ratio tests comparing nested generalized linear models. χ^2 represents the difference in deviance or log-likelihood between compared models, *N* indicates the number of observations, and Cohen's w denotes the effect size associated with the likelihood ratio test.

*** $p < .001$, ** $p < .01$, * $p < .05$

Figure Captions

Figure 1. Significant effects of bilingual status or its interaction with sex on neuropsychological functioning outcomes

NOTE. Active bilinguals outperformed passive bilinguals across measures, which was specific to female participants for the VOSP number location, only (Panel F). Asterisks indicate significant group comparisons after correction: *** $p < .001$, ** $p < .01$, * $p < .05$. The red dots and vertical lines in box plots for significant main effects (Panels A through E) represent predicted means and 95% confidence intervals computed from the optimal model, respectively. The error bars in the bar graphs for the significant interaction (Panel F) represent 95% confidence interval of the estimated means. Abbreviations: TMT: Trail Making Test. BNT: Boston Naming Test. CERAD: Consortium to Establish a Registry for Alzheimer's Disease. VOSP: Visual Object Space and Perception.

Figure 2. Significant effects of bilingual status alongside its interaction with sex or education on biomarker levels

NOTE. Active bilinguals exhibited more favorable profiles in CSF Aβ-42/40 ratio (male participants; Panel A), CSF YKL-40 (female participants; B), and CSF GFAP (participants with

higher education; C), as well as less favorable profiles in plasma GFAP (D) and CSF Aβ-42 (female participants; E). Asterisks indicate significant group comparisons after correction: *** p < .001, ** p < .01, * p < .05. The error bars in the bar graphs (Panels A, B, and E) and line graphs (Panel C) for significant interactions represent 95% confidence interval of the estimated means. The red dots and vertical lines in box plots (Panel D) for significant main effects represent predicted means and 95% confidence intervals computed from the optimal model, respectively.

Abbreviations: CSF: cerebrospinal fluid. Aβ: Amyloid-beta. YKL-40: Chitinase-3-like protein 1 (CHI3L1, also known as YKL-40). GFAP: glial fibrillary acidic protein.

Figure 3. Diagrams illustrating the mediation effects of biofluid markers on the relationship between bilingual status and neuropsychological functioning

NOTE. The mediation or indirect effect (ACME), direct effect (ADE), and total effect are reported. The p-value and 95% CI were estimated using bootstrapping samples. No significant mediation effects were found across measures. N represents the number of participants with data of the biomarker, neuropsychological measure, and covariates (i.e., education, sex, age, and MMSE). The mediator model included the treatment and mediator, whereas the outcome model also included the outcome.

Abbreviations: ACME: average causal mediation effect. ADE: average direct effect. CSF: cerebrospinal fluid. YKL-40: Chitinase-3-like protein 1 (CHI3L1). TMT: Trail Making Test. Aβ: Amyloid-beta. GFAP: glial fibrillary acidic protein. CERAD: Consortium to Establish a Registry for Alzheimer's Disease.